Inhalation solution approved for bronchospasm in children. (Product Marketplace).
Sepracor announces that the U.S. Food and Drug Administration (FDA FDA
Food and Drug Administration
n.pr See Food and Drug Administration.
n.pr the abbreviation for the Food and Drug Administration. ) has approved Xopenex[R] brand levalbuterol HCI inhalation solution for the treatment or prevention of bronchospasm in children 6 to 11 years old with reversible obstructive airway disease, such as asthma. Xopenex will be marketed for use in a nebulizer nebulizer /neb·u·liz·er/ (neb´u-li?zer) atomizer; a device for throwing a spray.
n. at dosage strengths of 0.31 and 0.63 mg for pediatric patients. This product has been marketed at dosage strengths of 0.63 and 1.25 mg for patients 12 years of age and older since May 1999.
Results of a multicenter, randomized ran·dom·ize
tr.v. ran·dom·ized, ran·dom·iz·ing, ran·dom·iz·es
To make random in arrangement, especially in order to control the variables in an experiment. , double-blind, placebo-controlled pediatric pediatric /pe·di·at·ric/ (pe?de-at´rik) pertaining to the health of children.
Of or relating to pediatrics. study were included in the supplemental New Drug Application (sNDA) submission to the FDA in March 2001. In one of the largest pediatric asthma studies ever conducted for a beta-agonist (n = 338), the safety and efficacy of levalbuterol inhalation solution were evaluated at dosage strengths of 0.31 and 0.63 mg, and racemic racemic /ra·ce·mic/ (ra-se´mik) optically inactive, being composed of equal amounts of dextrorotatory and levorotatory isomers.
adj. Abbr. albuterol inhalation solution at dosage strengths of 1.25 and 2.5 mg, compared with placebo, in patients with mild to moderate asthma. Both pediatric dosage strengths of levalbuterol were found to be safe and effective, according to lead investigator Henry Milgrom, MD. The study was published in the December 2001 issue of The Journal of Allergy and Clinical Immunology The Journal of Allergy and Clinical Immunology is a scientific journal in the field of allergy and immunology, with an emphasis on clinical relevance. It's the official journal of the American Academy of Allergy, Asthma, and Immunology. .
The 0.31-mg dose is the lowest pediatric Xopenex dose approved by the FDA for the treatment or prevention of bronchospasm. This dose was found to be effective and to have an acceptable beta-mediated side effect profile. The recommended dosage for patients 6 to 11 years of age is 0.31 mg administered three times a day by nebulization nebulization /neb·u·li·za·tion/ (neb?u-li-za´shun)
1. conversion into an aerosol or spray.
2. treatment by an aerosol. . Routine dosing should not exceed 0.63 mg three times a day.
Adverse events that occurred in [greater than or equal to]2% of patients receiving Xopenex inhalation solution or racemic albuterol and more frequently than patients receiving placebo included flu syndrome, tachycardia or increased heart rate, nervousness, and tremor.
Circle 127 on Reader Service Card